Cabozantinib is an orally administered, RTK inhibitor of multiple kinases effecting cancer cell growth, angiogenesis, and metabolism including MET, VEGFR2/KDR, AXL, TIE2, RET, and KIT. This evidence concerns the gene KDR and cancer.